胃排空
胰高血糖素样肽-1
肺吸入
医学
胰高血糖素样肽1受体
围手术期
利拉鲁肽
药方
受体
内科学
重症监护医学
内分泌学
麻醉
药理学
胃
糖尿病
兴奋剂
2型糖尿病
作者
Mark L. van Zuylen,Sarah E. Siegelaar,Mark P. Plummer,Adam M. Deane,Jeroen Hermanides,Abraham H. Hulst
标识
DOI:10.1016/j.bja.2024.01.001
摘要
Summary
Prescriptions and use of glucagon-like peptide-1 (GLP-1) receptor agonists are increasing dramatically, as indications are expanding from the treatment of diabetes mellitus to weight loss for people with obesity. As GLP-1 receptor agonists delay gastric emptying, perioperative healthcare practitioners could be concerned about an increased risk for pulmonary aspiration during general anaesthesia. We summarise relevant medical literature and provide evidence-based recommendations for perioperative care for people taking GLP-1 receptor agonists. GLP-1 receptor agonists delay gastric emptying; however, ongoing treatment attenuates this effect. The risk of aspiration during general anaesthesia is unknown. However, we advise caution in patients who recently commenced on GLP-1 receptor agonists. After over 12 weeks of treatment, standard fasting times likely suffice to manage the risk of pulmonary aspiration for most otherwise low-risk patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI